Study protocol to evaluate MN-001’s (tipelukast) efficacy, safety and tolerability in subjects with non-alcoholic fatty liver disease (NAFLD), hypertriglyceridemia (HTG) and type-2 diabetes mellitus (T2DM)

Saved in:
Bibliographic Details
Published inAtherosclerosis Vol. 395; p. 118063
Main Authors Matsuda, Kazuko, Makhay-Bozym, Malath, Iwaki, Yuichi
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.08.2024
Online AccessGet full text

Cover

More Information
ISSN:0021-9150
DOI:10.1016/j.atherosclerosis.2024.118063